In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on PolarityTE (PTE), with a price target of $3.00. The company’s shares closed last Tuesday at $1.18, close to its 52-week low of $0.78.
According to TipRanks.com, Byrnes has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.4% and a 29.5% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Opiant Pharmaceuticals, and Aridis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PolarityTE with a $3.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.08 and a one-year low of $0.78. Currently, PolarityTE has an average volume of 1.37M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolarityTE, Inc. is a commercial-stage biotechnology and regenerative biomaterials company, which focuses on discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its products include SkinTE, OsteoTE and Real Time Assistant. The company was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.
